• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Elicera Therapeutics

2.44 SEK

-3.94 %

Less than 1K followers

ELIC

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-3.94 %
-22.95 %
-61.47 %
-52.03 %
-58.26 %
-59.48 %
-21.74 %
-
-59.61 %

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.

Read more
Market cap
162.84M SEK
Turnover
1.74M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
21/8
2026

Interim report Q2'26

27/11
2026

Interim report Q3'26

16/2
2027

Annual report '26

Regulatory press releaseyesterday

Elicera Therapeutics: Eliceras valberedning föreslår Margareth Jorvid som ny styrelseordförande

Elicera Therapeutics
Regulatory press releaseyesterday

Elicera Therapeutics: Elicera's Nomination Committee Proposes Margareth Jorvid as New Chair of the Board

Elicera Therapeutics
Regulatory press release6/3/2026, 3:01 PM

Elicera Therapeutics: Elicera publishes annual report for 2025

Elicera Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release6/3/2026, 3:01 PM

Elicera Therapeutics: Elicera publicerar årsredovisningen för 2025

Elicera Therapeutics
Regulatory press release6/1/2026, 3:46 PM

Elicera Therapeutics: Elicera offentliggör utfall i Företrädesemission

Elicera Therapeutics
Regulatory press release6/1/2026, 3:46 PM

Elicera Therapeutics: Elicera announces outcome of the rights issue

Elicera Therapeutics
Press release5/25/2026, 7:10 AM

Elicera Therapeutics meddelar att slutrapportering och slutgiltig utbetalning från EIC Accelerator för CARMA-studien har godkänts

Elicera Therapeutics
Press release5/25/2026, 7:10 AM

Elicera Therapeutics announces that the final reporting and final payment from the EIC Accelerator for the CARMA study have been approved

Elicera Therapeutics
Regulatory press release5/22/2026, 6:01 AM

Kallelse till årsstämma i Elicera Therapeutics AB (publ)

Elicera Therapeutics
Press release5/19/2026, 8:10 AM

DNB Carnegie Access: Elicera Therapeutics - Extended company presentation and Q&A

Elicera Therapeutics
Press release5/19/2026, 5:42 AM

Elicera Therapeutics publicerar presentation och Q&A

Elicera Therapeutics
Press release5/13/2026, 1:57 PM

Elicera Therapeutics CSO tar tillfälligt ledigt för att genomgå medicinsk behandling - Di Yu utses till biträdande CSO

Elicera Therapeutics
Press release5/13/2026, 1:57 PM

Elicera Therapeutics' CSO takes temporary leave to undergo medical treatment - Di Yu appointed Acting CSO

Elicera Therapeutics
Press release5/12/2026, 2:55 PM

Carlsquare: Analysuppdatering Elicera Therapeutics: Höjer insatserna efter framsteg

Elicera Therapeutics
Regulatory press release5/11/2026, 12:16 PM

Elicera Therapeutics: Elicera offentliggör informationsdokument inför företrädesemissionen

Elicera Therapeutics
Regulatory press release5/11/2026, 12:16 PM

Elicera Therapeutics: Elicera publishes information document regarding the rights issue

Elicera Therapeutics
Regulatory press release5/8/2026, 11:29 AM

Kommuniké från extra bolagsstämma i Elicera Therapeutics AB (publ) den 8 maj 2026

Elicera Therapeutics
Press release4/21/2026, 6:53 PM

DNB Carnegie Access: Elicera Therapeutics: Withdrawing fair value following rights issue announcement - Correction

Elicera Therapeutics
Press release4/21/2026, 9:15 AM

DNB Carnegie Access: Elicera Therapeutics: Withdrawing fair value following rights issue announcement

Elicera Therapeutics
Press release4/21/2026, 8:45 AM

Carlsquare: Första intrycket Elicera Therapeutics kv1 2026: Företrädesemission om 73 MSEK

Elicera Therapeutics